Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Apr 3;82(9):1547–1552. doi: 10.1054/bjoc.2000.1176

Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease

L S Dobson 1, P C Lorigan 1, R E Coleman 1, B W Hancock 1
PMCID: PMC2363400  PMID: 10789722

Abstract

Persistent gestational trophoblastic disease is potentially fatal, but the majority of patients are cured with chemotherapy. Any developments in treatment are therefore being directed towards maintaining efficacy and reducing toxicity. We evaluated efficacy and toxicity of methotrexate, etoposide and dactinomycin (MEA) as first-line therapy for high risk disease and etoposide and dactinomycin (EA) as second-line therapy for methotrexate-refractory low risk disease in a retrospective analysis of 73 patients (38 MEA, 35 EA) treated since 1986 at a supra-regional centre. The median follow-up period was 5.5 years and the median number of cycles received was 7. The overall complete response rate was 85% (97% for EA, 75% for MEA). Of eight patients who failed to respond, four have since died and four were cured with platinum-based chemotherapy. Alopecia was universal. Grade II or worse nausea, emesis, or stomatitis was observed in 29%, 30% and 37% respectively. Fifty-one per cent experienced grade II/III anaemia, 8% grade II or higher thrombocytopenia and 64% grade III or IV neutropenia; in six cases this was complicated by sepsis. Fifty-four per cent of patients went on to have a normal pregnancy. No patient has developed a second malignancy. In conclusion, the MEA and EA chemotherapy regimens for persistent trophoblastic disease are very well tolerated, do not appear to affect future fertility and are associated with excellent, sustained complete response rates. © 2000 Cancer Research Campaign

Keywords: gestational trophoblastic disease, combination chemotherapy

Full Text

The Full Text of this article is available as a PDF (83.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ayhan A., Yapar E. G., Deren O., Kişnişi H. Remission rates and significance of prognostic factors in gestational trophoblastic tumors. J Reprod Med. 1992 May;37(5):461–465. [PubMed] [Google Scholar]
  2. Bagshawe K. D., Dent J., Newlands E. S., Begent R. H., Rustin G. J. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol. 1989 Jul;96(7):795–802. doi: 10.1111/j.1471-0528.1989.tb03318.x. [DOI] [PubMed] [Google Scholar]
  3. Bagshawe K. D. Risk and prognostic factors in trophoblastic neoplasia. Cancer. 1976 Sep;38(3):1373–1385. doi: 10.1002/1097-0142(197609)38:3<1373::aid-cncr2820380342>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  4. Bower M., Newlands E. S., Holden L., Short D., Brock C., Rustin G. J., Begent R. H., Bagshawe K. D. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol. 1997 Jul;15(7):2636–2643. doi: 10.1200/JCO.1997.15.7.2636. [DOI] [PubMed] [Google Scholar]
  5. DuBeshter B., Berkowitz R. S., Goldstein D. P., Cramer D. W., Bernstein M. R. Metastatic gestational trophoblastic disease: experience at the New England Trophoblastic Disease Center, 1965 to 1985. Obstet Gynecol. 1987 Mar;69(3 Pt 1):390–395. [PubMed] [Google Scholar]
  6. Dubuc-Lissoir J., Zweizig S., Sweizig S., Schlaerth J. B., Morrow C. P. Metastatic gestational trophoblastic disease: a comparison of prognostic classification systems. Gynecol Oncol. 1992 Apr;45(1):40–45. doi: 10.1016/0090-8258(92)90488-5. [DOI] [PubMed] [Google Scholar]
  7. Gillespie A. M., Siddiqui N., Coleman R. E., Hancock B. W. Gestational trophoblastic disease: does central nervous system chemoprophylaxis have a role? Br J Cancer. 1999 Mar;79(7-8):1270–1272. doi: 10.1038/sj.bjc.6690203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Goldstein D. P., Berkowitz R. S. Prophylactic chemotherapy of complete molar pregnancy. Semin Oncol. 1995 Apr;22(2):157–160. [PubMed] [Google Scholar]
  9. Hammond C. B., Borchert L. G., Tyrey L., Creasman W. T., Parker R. T. Treatment of metastatic trophoblastic disease: good and poor prognosis. Am J Obstet Gynecol. 1973 Feb 15;115(4):451–457. doi: 10.1016/0002-9378(73)90389-x. [DOI] [PubMed] [Google Scholar]
  10. Kennedy A. W. Persistent nonmetastatic gestational trophoblastic disease. Semin Oncol. 1995 Apr;22(2):161–165. [PubMed] [Google Scholar]
  11. Lurain J. R. High-risk metastatic gestational trophoblastic tumors. Current management. J Reprod Med. 1994 Mar;39(3):217–222. [PubMed] [Google Scholar]
  12. Newlands E. S., Bagshawe K. D., Begent R. H., Rustin G. J., Holden L., Dent J. Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984). Br J Obstet Gynaecol. 1986 Jan;93(1):63–69. doi: 10.1111/j.1471-0528.1986.tb07815.x. [DOI] [PubMed] [Google Scholar]
  13. Newlands E. S., Bagshawe K. D., Begent R. H., Rustin G. J., Holden L. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol. 1991 Jun;98(6):550–557. doi: 10.1111/j.1471-0528.1991.tb10369.x. [DOI] [PubMed] [Google Scholar]
  14. Quinn M., Murray J., Friedlander M., Steigrad S., Khoo S., Marsden D., Hammond I., Jobling T. EMACO in high risk gestational trophoblast disease--the Australian experience. Gestational Trophoblast Subcommittee, Clinical Oncological Society of Australia. Aust N Z J Obstet Gynaecol. 1994 Feb;34(1):90–92. doi: 10.1111/j.1479-828x.1994.tb01047.x. [DOI] [PubMed] [Google Scholar]
  15. Soper J. T., Clarke-Pearson D. L., Berchuck A., Rodriguez G., Hammond C. B. 5-day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol. 1994 Jul;54(1):76–79. doi: 10.1006/gyno.1994.1169. [DOI] [PubMed] [Google Scholar]
  16. Soper J. T., Evans A. C., Clarke-Pearson D. L., Berchuck A., Rodriguez G., Hammond C. B. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. Obstet Gynecol. 1994 Jan;83(1):113–117. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES